Renaissance Technologies’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-581,300
| Closed | -$1.07M | – | 4431 |
|
|
2023
Q1 | $1.07M | Buy |
581,300
+304,404
| +110% | +$377K | ﹤0.01% | 2436 |
|
|
2022
Q4 | $307K | Buy |
276,896
+197,196
| +247% | +$281K | ﹤0.01% | 3208 |
|
|
2022
Q3 | $186K | Sell |
79,700
-131,381
| -62% | -$465K | ﹤0.01% | 3409 |
|
|
2022
Q2 | $640K | Buy |
211,081
+192,981
| +1,066% | +$939K | ﹤0.01% | 2999 |
|
|
2022
Q1 | $123K | Buy |
+18,100
| New | +$129K | ﹤0.01% | 3760 |
|
|
2021
Q3 | – | Sell |
-133,300
| Closed | -$906K | – | 3969 |
|
|
2021
Q2 | $906K | Buy |
133,300
+113,990
| +590% | +$947K | ﹤0.01% | 2716 |
|
|
2021
Q1 | $198K | Sell |
19,310
-111,204
| -85% | -$1.22M | ﹤0.01% | 3155 |
|
|
2020
Q4 | $914K | Sell |
130,514
-169,600
| -57% | -$1.32M | ﹤0.01% | 2549 |
|
|
2020
Q3 | $2.45M | Sell |
300,114
-196,500
| -40% | -$1.22M | ﹤0.01% | 2010 |
|
|
2020
Q2 | $3.43M | Sell |
496,614
-203,500
| -29% | -$1.1M | ﹤0.01% | 1859 |
|
|
2020
Q1 | $3.33M | Buy |
700,114
+290,200
| +71% | +$1.67M | ﹤0.01% | 1792 |
|
|
2019
Q4 | $3.58M | Buy |
409,914
+361,006
| +738% | +$1.95M | ﹤0.01% | 2047 |
|
|
2019
Q3 | $163K | Buy |
48,908
+37,308
| +322% | +$149K | ﹤0.01% | 3195 |
|
|
2019
Q2 | $57K | Sell |
11,600
-1,200
| -9% | -$6.37K | ﹤0.01% | 3441 |
|
|
2019
Q1 | $79K | Sell |
12,800
-199,200
| -94% | -$962K | ﹤0.01% | 3328 |
|
|
2018
Q4 | $714K | Buy |
212,000
+44,953
| +27% | +$210K | ﹤0.01% | 2723 |
|
|
2018
Q3 | $1.09M | Buy |
+167,047
| New | +$1.24M | ﹤0.01% | 2570 |
|
Other funds holding JNCE
Renaissance Technologies's JNCE Position: Q2 2023 in Review
Renaissance Technologies sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 581,300 shares — an estimated $1.07M sold.
Renaissance Technologies first reported a position in JNCE in Q3 2018 and held it in 17 quarters. The position peaked at $3.58M in Q4 2019. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Renaissance Technologies reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Renaissance Technologies sold 581,300 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.07M.
- Renaissance Technologies first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and held it in 17 quarters.
- Renaissance Technologies's Jounce Therapeutics, Inc. Common Stock position peaked at $3.58M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.